SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-003608
Filing Date
2022-02-02
Accepted
2022-02-02 16:05:22
Documents
14
Period of Report
2022-02-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-8k_20220202.htm   iXBRL 8-K 37235
2 EX-99.1 arwr-ex991_6.htm EX-99.1 144058
3 GRAPHIC gawqmb2guf5t000001.jpg GRAPHIC 49974
  Complete submission text file 0001564590-22-003608.txt   389779

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA arwr-20220202.xsd EX-101.SCH 5729
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE arwr-20220202_lab.xml EX-101.LAB 19433
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE arwr-20220202_pre.xml EX-101.PRE 11611
8 EXTRACTED XBRL INSTANCE DOCUMENT arwr-8k_20220202_htm.xml XML 3561
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

IRS No.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 22583605
SIC: 2834 Pharmaceutical Preparations